ACLY
ATP-citrate synthase
As of the edition of 20 October 2026, ACLY (ATP-citrate synthase, UniProt P53396) has 2 drugs tested at it and 4 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P53396
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 36
- Disease areas
- Nutrition and metabolism; Heart and blood vessels; Inherited and neonatal; Hormones; Digestive system; Immune system; Infections; Urinary and reproductive
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Status not established | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bempedoic acid | Marketed | Phase 4 | Ends 2040 |
| BGT-002 | Status not established | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Esperion Therapeutics | Route B |
| Otsuka | Route B |
| Daiichi Sankyo | Route B |
The other 1 company at ACLY
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at ACLY, ranked, with the facts behind eachRequest access. Nothing is shown until you do.